Angelini Pharma Buys US Catalyst for $4.1 Billion in State-Backed Deal
Angelini is set to buy US-based Catalyst for $31.50 per share in a state-backed deal, expanding into rare neurological diseases and entering the US market.
/ 2 items
Angelini is set to buy US-based Catalyst for $31.50 per share in a state-backed deal, expanding into rare neurological diseases and entering the US market.
Angelini Pharma may buy Catalyst Pharmaceuticals. Talks are early, but news pushed Catalyst’s stock up. No deal is certain yet.